Deducing from our results, targeting SOX17 or the WNT, TGF‐beta / Activin, or FGF signaling pathways in combination with cisplatin might be a promising way to block the escape route of GCT under therapy, i.e., formation of a YST.53 The gene discussed is TGFB1; the disease is granular cell tumor.